Kimberly-Clark is acquiring Tylenol maker Kenvue in a $48.7 billion cash-and-stock deal, creating a major consumer health goods company if shareholders approve.

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

Bank of America's stock has lagged behind rivals, notably industry leader JPMorgan Chase, over the past five years. Financial Services Roundup: Market Talk Find insight on Westpac, Deterra Royalties ...

Asian shares are trading mixed after overseas markets got a big lift from optimism over AI technology. Shares rose in Hong Kong on Tuesday, while slipping in Tokyo, Sydney and Seoul. On Wall ...

In this piece, we will look at the stocks Jim Cramer discussed.

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling Palantir - whose stock has more than doubled this year on AI excitement and ...

Dow Jones Top Company Headlines at 5 AM ET: Saudi Aramco's Net Profit Rises on Higher Production, Oil Prices | BP ... Third-quarter profit rose compared with the prior three-month period but declined ...

One of the biggest mergers of the year, worth $49 billion, comes just weeks after the Trump administration linked the common ...